Immunologic response to collagen-impregnated vascular grafts: a randomized prospective study. The Canadian Multicenter Hemashield Study Group.
The potential for bovine collagen-impregnated vascular prostheses to stimulate an immune response was tested in 128 patients randomized prospectively to receive either a Dacron graft or a Dacron graft with collagen coating. Clinical variables and laboratory tests for antibovine collagen antibody were used to identify patients who developed humoral immunity up to 6 months after graft implantation. In a subgroup of 20 subjects, a lymphocyte proliferation assay by freshly isolated leukocytes was used to test for cell-mediated immune response. Of the patients randomized to receive a collagen-coated graft, five showed seroconversion to bovine, type I collagen. Seroconversion also occurred in one of the patients randomized to the noncollagen coated graft. No patient had a positive lymphocyte proliferation response, indicating an absence of cell-mediated immune response. No evidence for the development of cross-reactivity with human collagen was seen. The potential for bovine collagen to stimulate an immune response after implantation of a collagen-coated graft is low. The response is weak, and when it does occur it appears to be without clinical consequences.
D000818:Animals; D000906:Antibodies / Q000097:blood; D000917:Antibody Formation / Q000276:immunology; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D002170:Canada; D002417:Cattle; D003094:Collagen / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D011093:Polyethylene Terephthalates; D011446:Prospective Studies; D011474:Prosthesis Design
D000906:Antibodies; D011093:Polyethylene Terephthalates; D003094:Collagen